Candesartan in the treatment of hypertension: what have we learnt in the last decade?

被引:6
作者
Barrios, Vivencio [1 ]
Escobar, Carlos [2 ]
机构
[1] Hosp Ramon & Cajal, Dept Cardiol, E-28034 Madrid, Spain
[2] Hosp Infanta Sofia, Dept Cardiol, Madrid, Spain
关键词
blood pressure; candesartan; efficacy; heart failure; hypertension; left ventricular hypertrophy; microalbuminuria; safety; LEFT-VENTRICULAR HYPERTROPHY; CHRONIC HEART-FAILURE; BLOCKER-BASED REGIMEN; CONVERTING-ENZYME INHIBITORS; BLOOD-PRESSURE CONTROL; CARDIOVASCULAR RISK; DOUBLE-BLIND; ANGIOTENSIN RECEPTORS; COMBINATION THERAPY; CLINICAL-PRACTICE;
D O I
10.1517/14740338.2011.608064
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Although all of the first-line antihypertensive drugs effectively reduce blood pressure, there are some conditions that may favor the use of angiotensin receptor blockers over others, such as left ventricular hypertrophy, microalbuminuria, renal dysfunction, diabetes, or metabolic syndrome, among others. Areas covered: This manuscript reviewed the data supporting the use of candesartan cilexetil in hypertensive population with a special focus on its efficacy and safety. For this purpose, a search on MEDLINE and EMBASE databases was performed. The MEDLINE and EMBASE search included both medical subject headings (MeSH) and keywords including: candesartan OR angiotensin receptor blockers OR renin angiotensin system AND hypertension treatment. References of the retrieved articles were also screened for additional studies. There were no language restrictions. Expert opinion: Candesartan, a long-acting angiotensin receptor antagonist, has been shown to be an effective and well-tolerated therapy in the entire spectrum of hypertensive patients, including those at higher risk, such as those with diabetes, metabolic syndrome, left ventricular hypertrophy, or microalbuminuria.
引用
收藏
页码:957 / 968
页数:12
相关论文
共 54 条
[1]   A large scale study of angiotensin II inhibition therapy in an elderly population: the CHANCE study [J].
Asmar, Roland ;
Nisse-Durgeat, Sophie .
VASCULAR HEALTH AND RISK MANAGEMENT, 2006, 2 (03) :317-323
[2]  
Bakris G, 2001, J Clin Hypertens (Greenwich), V3, P16, DOI 10.1111/j.1524-6175.2001.00826.x
[3]   Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain.: The CONTROLRISK study [J].
Barrios, V. ;
Escobar, C. ;
Calderon, A. ;
Echarri, R. ;
Gonzalez-Pedel, V. ;
Ruilope, L. M. .
JOURNAL OF HUMAN HYPERTENSION, 2007, 21 (06) :479-485
[4]  
Barrios Vivencio, 2007, Expert Rev Cardiovasc Ther, V5, P825, DOI 10.1586/14779072.5.5.825
[5]   Adverse events in clinical trials: is a new approach needed? [J].
Barrios, Vivencio ;
Escobar, Carlos ;
Prieto, Luis ;
Herranz, Inmaculada .
LANCET, 2008, 372 (9638) :535-536
[6]   Regression of left ventricular hypertrophy in diabetics by a candesartan-based regimen in clinical practice [J].
Barrios, Vivencio ;
Escobar, Carlos ;
Calderon, Alberto ;
Vegazo, Onofre ;
Fernandez, Raul ;
Asin, Enrique .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 77 (03) :492-493
[7]   Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice: the SARA study [J].
Barrios, Vivencio ;
Calderon, Alberto ;
Escobar, Carlos ;
Barrios, Sara ;
Navarro-Cid, Josefa ;
Gonzalez-Pedel, Victoria ;
Vegazo, Onofre ;
Fernandez, Raul .
JOURNAL OF HYPERTENSION, 2007, 25 (09) :1967-1973
[8]   Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice.: The VIPE study [J].
Barrios, Vivencio ;
Escobar, Carlos ;
Calderon, Alberto ;
Pablo Tomas, Juan ;
Ruiz, Soledad ;
Luis Moya, Jose ;
Megias, Alicia ;
Vegazo, Onofre ;
Fernandez, Raul .
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2006, 7 (04) :236-242
[9]   Cardiovascular protection with candesartan in patients with metabolic disorders [J].
Barrios, Vivencio ;
Escobar, Carlos ;
Calderon, Alberto .
HYPERTENSION RESEARCH, 2010, 33 (12) :1312-1313
[10]   Gender differences in the diagnosis and treatment of left ventricular hypertrophy detected by different electrocardiographic criteria. Findings from the SARA study [J].
Barrios, Vivencio ;
Escobar, Carlos ;
Calderon, Alberto ;
Barrios, Sara ;
Navarro-Cid, Josefa ;
Ferrer, Elena ;
Echarri, Rocio .
HEART AND VESSELS, 2010, 25 (01) :51-56